Legend Biotech Corporation (LEGN) is a global biopharmaceutical company — traded in the U.S. as an ADR (American Depositary Receipt) — best known for Carvykti, a CAR-T (chimeric antigen receptor T-cell) therapy for multiple myeloma developed in partnership with Johnson & Johnson's Janssen unit. After a steep decline, the shares now trade near $19, while the average of the current analyst price targets sits much higher. That raises a straightforward question: can LEGN stock reach $45?
The central target used here is the arithmetic mean of nine current analyst price targets attributed to specific firms and dates. The most recent calls include J.P. Morgan at $33 (Hold, October 2026), RBC Capital at $56 (Outperform, October 2026), UBS at $24 (Hold, October 2026), H.C. Wainwright at $65 (Buy, September 2026), Barclays at $68 (Overweight, October 2026, lowered from $74), Goldman Sachs at $38 (Buy, October 2026), Morgan Stanley at $48 (Overweight, August 2026), Oppenheimer at $40 (Hold, downgraded from Outperform in August 2026), and TD Cowen at $29 (Hold, May 2026). The average of these nine targets is roughly $44.56, rounded to $45.
The dispersion is striking: the range spans $24 to $68. Bullish analysts point to Carvykti's durable demand and underpenetrated earlier-line treatment markets, while more cautious analysts cite competition from bispecific antibodies and rival CAR-T therapies, financing overhang, and execution uncertainty. Third-party aggregators report a broader consensus in the $46 to $55 area across roughly 13 to 15 analysts, but the nine individually verifiable targets above are the basis for the $45 figure used throughout this article.
LEGN shares closed near $19.01, down roughly 40% over the past 52 weeks and sitting well below their 52-week high near $38. Reaching $45 would require about 137% upside from current levels — a very large move that would exceed even the stock's prior peak. Trailing twelve-month revenue is about $1.27 billion, with a net loss of roughly $91.5 million, though the company reached adjusted net income profitability in the second quarter of 2026 for the first time. The path toward the target would likely depend on sustained Carvykti sales growth, expanding international commercialization, and evidence that profitability is durable rather than a single-quarter result.
Carvykti remains the central driver. Partner Janssen reported preliminary net trade sales of about $710 million for the third quarter of 2026, up roughly 35% year over year, with nine-month sales of about $1.96 billion. Johnson & Johnson has reiterated Carvykti's potential to exceed $5 billion in annual sales. The company holds roughly $965 million in cash with no long-term debt, and management has said it expects to remain adjusted-net-income profitable through the second half of 2026. Analysts also flag upcoming catalysts such as CARTITUDE-5 data, in vivo pipeline readouts, and a planned investigational new drug filing for LB2501.
The biggest near-term obstacles are structural rather than fundamental. The company completed a roughly $225 million equity offering in June 2026 and filed in October for up to a further $178.8 million, creating a persistent supply overhang that has capped rallies. A recent CEO departure and Oppenheimer's downgrade to Hold, which cited merger-and-acquisition and financing concerns, have added caution. Competition is intensifying: Bristol Myers Squibb's rival Abecma has lost momentum, but newer bispecific antibodies and incoming CAR-T entrants could pressure Carvykti's growth and pricing. Valuation skepticism and the stock's downtrend have so far outweighed strong product sales.
The technical picture remains bearish. Shares trade below both the 50-day moving average near $19.71 and the 200-day average near $22.26, with the 50-day below the 200-day. The $20 level has acted as resistance, and the 52-week low near $16.24 is a key support zone. A durable recovery would likely require the stock to reclaim and hold above $20, then the 200-day average, before any move toward higher analyst targets becomes realistic.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary. The next earnings report is scheduled for November 11, 2026, and investors should watch confirmed Carvykti sales, gross margin trends, and guidance on adjusted profitability. Other items to monitor include further analyst revisions, any additional equity issuance, CARTITUDE-5 and pipeline data readouts, regulatory decisions, and competitive launches in the BCMA (B-cell maturation antigen) multiple myeloma space.
For traders who want to track price action in real time, AI Daily Buy/Sell Signals from Tickeron offer a data-driven complement to fundamental research. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. Consider exploring AI Daily Buy/Sell Signals to help filter the daily noise around names like LEGN.
Can LEGN reach $45? The target is the rounded average of nine verifiable analyst price targets spanning $24 to $68, and it implies roughly 137% upside from a price near $19 — a very large move that would carry the stock past its prior 52-week high. The bull case rests on a genuinely growing blockbuster in Carvykti, a clean balance sheet, and a first step into profitability, but it is offset by a wide analyst range, repeated dilution, leadership turnover, and a persistent downtrend. Reaching $45 would require not just continued Carvykti execution but a meaningful re-rating of the stock. No outcome is assured, and the wide dispersion among analysts underscores that this is a high-uncertainty, high-optionality situation best monitored through earnings, pipeline catalysts, and any further capital raises.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LEGN has been loosely correlated with AXON. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LEGN jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To LEGN | 1D Price Change % | ||
|---|---|---|---|---|
| LEGN | 100% | +5.74% | ||
| AXON - LEGN | 37% Loosely correlated | +0.26% | ||
| AMLX - LEGN | 35% Loosely correlated | +4.47% | ||
| WVE - LEGN | 31% Poorly correlated | +7.48% | ||
| AMRN - LEGN | 31% Poorly correlated | -1.16% | ||
| ARRY - LEGN | 30% Poorly correlated | +7.62% | ||
More | ||||